3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
13
Gastrointestinal
2
Breast
2
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
92
Fallopian Tube Neoplasms
25
Breast Neoplasms
21
Endometrial Neoplasms
19
Carcinoma, Ovarian Epithelial
12
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Neoplasms
6
Fanconi Anemia, Complementation Group D1
5
Uterine Cervical Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Carcinoma, Renal Cell
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Peritoneal Neoplasms
2
Ovarian Diseases
2
Carcinosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Relapsed Ovarian Cancers Patients
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Platinum-sensitive Ovarian Cancer
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Interventions
pembrolizumab
18
Nivolumab
7
Carboplatin
7
durvalumab
5
Ipilimumab
5
aldesleukin
4
Paclitaxel
4
Irinotecan
4
Gemcitabine
4
Docetaxel
4
Cisplatin
4
sargramostim
3
atezolizumab
3
Topotecan
3
Polymerase Chain Reaction
3
Magnetic Resonance Spectroscopy
3
temsirolimus
2
talazoparib
2
carfilzomib
2
cabozantinib
2
budigalimab
2
Trastuzumab
2
Therapeutics
2
Taxes
2
Specimen Handling
2
Psychiatric Rehabilitation
2
Injections
2
Gene Expression Profiling
2
Fulvestrant
2
Fluorodeoxyglucose F18
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
olaparib
×
Gynecologic
×
Clear all
NCT02734004
2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2
Active not recruiting
264 enrolled
32 charts